GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
You may also be interested in...
FDA Starts Process For Regulating Next-generation Vaccine Adjuvants
Scientific meeting planned for late fall or early spring.
FDA Starts Process For Regulating Next-generation Vaccine Adjuvants
Scientific meeting planned for late fall or early spring.
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.